Sartorius Stedim Biotech (FR:DIM) has released an update.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sartorius Stedim Biotech has released its first-half 2024 financial results and provides forecasts for the rest of the year. The internationally active biopharmaceutical partner reported a turnover of approximately 2.8 billion euros in 2023 and employs around 10,600 people globally. The full investor news is available on the company’s website.
For further insights into FR:DIM stock, check out TipRanks’ Stock Analysis page.